CAR-T 세포 치료 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품 유형별, 종양 유형별, 적응증별, 치료 유형별, 표적 항원별, 최종사용자별, 지역별, 경쟁별(2020-2030년)

The Global CAR-T Cell Therapy Market, valued at USD 3.87 Billion in 2024, is projected to experience a CAGR of 22.77% to reach USD 13.25 Billion by 2030. Chimeric Antigen Receptor (CAR)-T cell therapy represents an advanced form of immunotherapy where a patient's T cells are genetically engineered to express a receptor targeting specific antigens on cancer cells. The market's expansion is primarily driven by the increasing global incidence of hematological malignancies, the demonstrated high efficacy and durable responses observed in relapsed or refractory patient populations, and substantial investment in research and development aimed at broadening therapeutic indications and enhancing treatment accessibility.

Key Market Drivers

The global CAR-T cell therapy market is significantly influenced by the demonstrated high efficacy of these treatments in hematologic malignancies and the expanding regulatory approvals for new indications. The proven ability of CAR-T therapies to induce deep and durable responses in patient populations with limited alternative options provides a compelling clinical rationale for their adoption and growth. For instance, according to Bristol Myers Squibb and 2seventy bio, in February 2023, the Phase 3 KarMMa-3 study demonstrated that Abecma achieved a 71% overall response rate in patients with relapsed or refractory multiple myeloma. This robust clinical performance underscores the transformative potential of CAR-T cells, driving demand and investment in this therapeutic area.

Key Market Challenges

The substantial cost associated with personalized CAR-T cell treatments represents a significant barrier to the global market's expansion. These high costs severely limit broader patient access and place considerable strain on healthcare systems, directly impeding the widespread adoption of these therapies. The financial burden creates substantial hurdles for both patients and healthcare providers, restricting the volume of treatments administered.

Key Market Trends

Expansion into Solid Tumor Indications represents a crucial diversification beyond the initial successes in hematologic malignancies, opening significant new market segments. The inherent complexities of solid tumors, such as their immunosuppressive microenvironments and heterogeneous antigen expression, have historically presented considerable challenges for CAR-T cell efficacy. However, ongoing research and technological innovations are addressing these barriers through enhanced CAR designs, localized delivery methods, and combinatorial approaches. Progress in this area is evidenced by the growing number of clinical investigations, with solid tumors constituting 24.6% of CAR-T clinical trials as of May 2025, according to insights from Frontiers. This expansion into a broader range of cancer types is pivotal for realizing the full therapeutic and commercial potential of CAR-T cell therapy, moving it towards a more widespread application in oncology.

Key Market Players

• Gilead Sciences, Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Cellectis SA
• Amgen Inc.
• Pfizer Inc
• Merck KgaA
• Intellia Therapeutics, Inc.
• Johnson & Johnson

Report Scope:

In this report, the Global CAR-T Cell Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

CAR-T Cell Therapy Market, By Product Type:

• Yescarta
• Kymriah
• Tecartus
• Breyanzi
• Abecma

CAR-T Cell Therapy Market, By Tumor Type:

• Hematological Malignancies
• Solid Tumors

CAR-T Cell Therapy Market, By Indication:

• Diffused Large B-Cell Lymphoma (DLBCL)
• Acute Lymphoblastic Leukemia (ALL)
• Follicular Lymphoma (FL)
• Mantle Cell Lymphoma (MCL)
• Others

CAR-T Cell Therapy Market, By Targeted Antigen:

• D 19
• BCMA (B-Cell Maturation Antigen)
• Others

CAR-T Cell Therapy Market, By End User:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

CAR-T Cell Therapy Market, By Treatment Type:

• Single Treatment
• Combination Treatment

CAR-T Cell Therapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global CAR-T Cell Therapy Market.

Available Customizations:

Global CAR-T Cell Therapy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global CAR-T Cell Therapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Yescarta, Kymriah, Tecartus, Breyanzi, Abecma)
  • 5.2.2. By Tumor Type (Hematological Malignancies, Solid Tumors)
  • 5.2.3. By Indication (Diffused Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Others)
  • 5.2.4. By Targeted Antigen (D 19, BCMA (B-Cell Maturation Antigen), Others)
  • 5.2.5. By End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.6. By Treatment Type (Single Treatment, Combination Treatment)
  • 5.2.7. By Region
  • 5.2.8. By Company (2024)
• 5.3. Market Map

6. North America CAR-T Cell Therapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Tumor Type
  • 6.2.3. By Indication
  • 6.2.4. By Targeted Antigen
  • 6.2.5. By End User
  • 6.2.6. By Treatment Type
  • 6.2.7. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States CAR-T Cell Therapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Tumor Type
      • 6.3.1.2.3. By Indication
      • 6.3.1.2.4. By Targeted Antigen
      • 6.3.1.2.5. By End User
      • 6.3.1.2.6. By Treatment Type
  • 6.3.2. Canada CAR-T Cell Therapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Tumor Type
      • 6.3.2.2.3. By Indication
      • 6.3.2.2.4. By Targeted Antigen
      • 6.3.2.2.5. By End User
      • 6.3.2.2.6. By Treatment Type
  • 6.3.3. Mexico CAR-T Cell Therapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Tumor Type
      • 6.3.3.2.3. By Indication
      • 6.3.3.2.4. By Targeted Antigen
      • 6.3.3.2.5. By End User
      • 6.3.3.2.6. By Treatment Type

7. Europe CAR-T Cell Therapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Tumor Type
  • 7.2.3. By Indication
  • 7.2.4. By Targeted Antigen
  • 7.2.5. By End User
  • 7.2.6. By Treatment Type
  • 7.2.7. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany CAR-T Cell Therapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Tumor Type
      • 7.3.1.2.3. By Indication
      • 7.3.1.2.4. By Targeted Antigen
      • 7.3.1.2.5. By End User
      • 7.3.1.2.6. By Treatment Type
  • 7.3.2. France CAR-T Cell Therapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Tumor Type
      • 7.3.2.2.3. By Indication
      • 7.3.2.2.4. By Targeted Antigen
      • 7.3.2.2.5. By End User
      • 7.3.2.2.6. By Treatment Type
  • 7.3.3. United Kingdom CAR-T Cell Therapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Tumor Type
      • 7.3.3.2.3. By Indication
      • 7.3.3.2.4. By Targeted Antigen
      • 7.3.3.2.5. By End User
      • 7.3.3.2.6. By Treatment Type
  • 7.3.4. Italy CAR-T Cell Therapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Tumor Type
      • 7.3.4.2.3. By Indication
      • 7.3.4.2.4. By Targeted Antigen
      • 7.3.4.2.5. By End User
      • 7.3.4.2.6. By Treatment Type
  • 7.3.5. Spain CAR-T Cell Therapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Tumor Type
      • 7.3.5.2.3. By Indication
      • 7.3.5.2.4. By Targeted Antigen
      • 7.3.5.2.5. By End User
      • 7.3.5.2.6. By Treatment Type

8. Asia Pacific CAR-T Cell Therapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Tumor Type
  • 8.2.3. By Indication
  • 8.2.4. By Targeted Antigen
  • 8.2.5. By End User
  • 8.2.6. By Treatment Type
  • 8.2.7. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China CAR-T Cell Therapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Tumor Type
      • 8.3.1.2.3. By Indication
      • 8.3.1.2.4. By Targeted Antigen
      • 8.3.1.2.5. By End User
      • 8.3.1.2.6. By Treatment Type
  • 8.3.2. India CAR-T Cell Therapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Tumor Type
      • 8.3.2.2.3. By Indication
      • 8.3.2.2.4. By Targeted Antigen
      • 8.3.2.2.5. By End User
      • 8.3.2.2.6. By Treatment Type
  • 8.3.3. Japan CAR-T Cell Therapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Tumor Type
      • 8.3.3.2.3. By Indication
      • 8.3.3.2.4. By Targeted Antigen
      • 8.3.3.2.5. By End User
      • 8.3.3.2.6. By Treatment Type
  • 8.3.4. South Korea CAR-T Cell Therapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Tumor Type
      • 8.3.4.2.3. By Indication
      • 8.3.4.2.4. By Targeted Antigen
      • 8.3.4.2.5. By End User
      • 8.3.4.2.6. By Treatment Type
  • 8.3.5. Australia CAR-T Cell Therapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Tumor Type
      • 8.3.5.2.3. By Indication
      • 8.3.5.2.4. By Targeted Antigen
      • 8.3.5.2.5. By End User
      • 8.3.5.2.6. By Treatment Type

9. Middle East & Africa CAR-T Cell Therapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Tumor Type
  • 9.2.3. By Indication
  • 9.2.4. By Targeted Antigen
  • 9.2.5. By End User
  • 9.2.6. By Treatment Type
  • 9.2.7. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia CAR-T Cell Therapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Tumor Type
      • 9.3.1.2.3. By Indication
      • 9.3.1.2.4. By Targeted Antigen
      • 9.3.1.2.5. By End User
      • 9.3.1.2.6. By Treatment Type
  • 9.3.2. UAE CAR-T Cell Therapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Tumor Type
      • 9.3.2.2.3. By Indication
      • 9.3.2.2.4. By Targeted Antigen
      • 9.3.2.2.5. By End User
      • 9.3.2.2.6. By Treatment Type
  • 9.3.3. South Africa CAR-T Cell Therapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Tumor Type
      • 9.3.3.2.3. By Indication
      • 9.3.3.2.4. By Targeted Antigen
      • 9.3.3.2.5. By End User
      • 9.3.3.2.6. By Treatment Type

10. South America CAR-T Cell Therapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Tumor Type
  • 10.2.3. By Indication
  • 10.2.4. By Targeted Antigen
  • 10.2.5. By End User
  • 10.2.6. By Treatment Type
  • 10.2.7. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil CAR-T Cell Therapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Tumor Type
      • 10.3.1.2.3. By Indication
      • 10.3.1.2.4. By Targeted Antigen
      • 10.3.1.2.5. By End User
      • 10.3.1.2.6. By Treatment Type
  • 10.3.2. Colombia CAR-T Cell Therapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Tumor Type
      • 10.3.2.2.3. By Indication
      • 10.3.2.2.4. By Targeted Antigen
      • 10.3.2.2.5. By End User
      • 10.3.2.2.6. By Treatment Type
  • 10.3.3. Argentina CAR-T Cell Therapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Tumor Type
      • 10.3.3.2.3. By Indication
      • 10.3.3.2.4. By Targeted Antigen
      • 10.3.3.2.5. By End User
      • 10.3.3.2.6. By Treatment Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global CAR-T Cell Therapy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Gilead Sciences, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Bristol-Myers Squibb Company
• 15.4. AbbVie Inc.
• 15.5. Cellectis SA
• 15.6. Amgen Inc.
• 15.7. Pfizer Inc
• 15.8. Merck KgaA
• 15.9. Intellia Therapeutics, Inc.
• 15.10. Johnson & Johnson

16. Strategic Recommendations

17. About Us & Disclaimer